Next, we determined whether pharmacologic inhibition of nuclear HMGB1 loss and release by glycyrrhizin prevents K-Ras-induced pancreatic cancer initiation under inflammatory conditions. The gene discussed is KRAS; the disease is familial pancreatic carcinoma.